Rodman & Renshaw Annual Global Investment Conference

September 10th - 12th, 2017

Lotte New York Palace Hotel, New York City

Rodman & Renshaw will host more than 300 public and private companies at the three-day 19th Annual Global Investment Conference in New York City. This year's conference will connect growth companies together with a vast audience of financial and strategic investors. The more than 2,000 attendees will enjoy access to corporate presentations from growth companies in the healthcare, natural resources, technology, media and telecommunications, cleantech and other industries; investor one-on-one meetings; keynote speakers; and daily networking opportunities over breakfast, lunch and cocktails. For more information on Rodman & Renshaw, visit

Conference Dates: A-M N-Z

Presenting Companies

NanoViricides (NNVC)

NanoViricides (NYSE: NNVC) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. For more information, visit the company website at

NantKwest (NK)

NantKwest (NASDAQ: NK) is a clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NantKwest's cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells; (2) Antibody-mediated killing using haNKs; and (3) Targeted activated killing using taNKs. For more information, visit the company website at

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals (NYSE: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. For more information, visit the company website at

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NASDAQ: NKTR) is a research-based biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. The company's R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar leverages its proprietary and proven chemistry platform in the discovery and design of new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. For more information, visit the company website at

NeuroMetrix (NURO)

NeuroMetrix (NASDAQ: NURO) is a commercial stage healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, visit the company website at

Neurotrope (NTRP)

Neurotrope (NASDAQ: NTRP) is developing a new approach to combatting Alzheimer's disease and other neurodegenerative diseases. In addition to the company's phase 2 trial of bryostatin-1 in moderate to severe Alzheimer's disease, Neurotrope has also conducted preclinical studies of bryostatin as a potential treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome—three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. For more information, visit the company website at

NeuroVive Pharmaceutical (NEVPF)

NeuroVive Pharmaceutical (OTC: NEVPF) is focused on mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. For more information, visit the company website at

New Age Beverages (NBEV)

New Age Beverages (NASDAQ: NBEV) is an all-natural tea and healthy functional beverage company. The company competes in the fast-growing healthy functional beverage segments including Ready to Drink (RTD) Tea, RTD Coffee, Kombucha, Energy Drinks, Relaxation Drinks, Coconut Waters and Functional Waters with the brands XingTea®, Marley One Drop®, Búcha® Live Kombucha, XingEnergy®, Marley Mellow Mood®, Coco-Libre®, and Aspen Pure® PH and Aspen Pure® Probiotic Water. The company's brands are sold across all 50 states within the US and in more than 10 countries. For more information, visit the company website at

Northern Dynasty Minerals (NAK)

Northern Dynasty Minerals (NYSE: NAK) is a mineral exploration and development company based in Vancouver, Canada. Northern Dynasty's principal asset, owned through its wholly-owned Alaska-based U.S. subsidiary Pebble Limited Partnership and other wholly-owned subsidiaries, is a 100% interest in a contiguous block of 2,402 mineral claims in southwest Alaska, including the Pebble deposit. The Pebble Partnership is the proponent of the Pebble Project, an initiative to develop one of the world's most important mineral resources. For more information, visit the company website at

NovaBay Pharmaceuticals (NBY)

NovaBay Pharmaceuticals (NYSE: NBY) is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets. For more information, visit the company website at

NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ: NVCR) is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. NovoCure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. For more information, visit the company website at

Novogen (NVGN)

Novogen (NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications. For more information, visit the company website at

ObsEva (OBSV)

ObsEva (NASDAQ: OBSV) is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. For more information, visit the company website at

Ocular Therapeutix (OCUL)

Ocular Therapeutix (NASDAQ: OCUL) is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidate, DEXTENZA™ for intracanalicular use has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery. For more information, visit the company website at

Onconova Therapeutics (ONTX)

Onconova Therapeutics (NASDAQ: ONTX) is a phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova's lead candidate, is a proprietary phase 3 small molecule agent, which the company believes blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. For more information, visit the company website at

OncoSec Medical (ONCS)

OncoSec Medical (NASDAQ: ONCS) is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. For more information, visit the company website at

OpGen (OPGN)

OpGen (NASDAQ: OPGN) is positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks. Using its large and ever-growing Acuitas Lighthouse® Database of pathogens from around the world, the company is developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. Through its CLIA-certified clinical laboratory services, OpGen provides rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. For more information, visit the company website at

Oragenics (OGEN)

Oragenics (NYSE: OGEN) is focused on becoming a world leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics has established two exclusive worldwide channel collaborations with Intrexon Corporation, a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. For more information, visit the company website at

Oramed Pharmaceuticals (ORMP)

Oramed Pharmaceuticals (NASDAQ: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed's PODTM technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company has completed multiple phase 2 clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. For more information, visit the company website at

Orexigen Therapeutics (OREX)

Orexigen Therapeutics (NASDAQ: OREX) is a biopharmaceutical company focused on the treatment of weight loss and obesity. The company's mission is to help improve the health and lives of patients struggling to lose weight. Orexigen's first product, Contrave®, was approved in the U.S. in September 2014. In the European Union, the medicine has been approved under the brand name Mysimba™. Orexigen is undertaking a range of development and commercialization activities, both on its own and with strategic partners, to bring Contrave / Mysimba to patients around the world. For more information, visit the company website at

Pacira Pharmaceuticals (PCRX)

Pacira Pharmaceuticals (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and patients. The company's flagship product, EXPAREL®, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. For more information, visit the company website at

Palatin Technologies (PTN)

Palatin Technologies (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For more information, visit the company website at

Paramount Gold Nevada (PZG)

Paramount Gold Nevada (NYSE: PZG) is a U.S.-based precious metals exploration company. Paramount has a high ratio of ounces of gold in mineral inventory to shares outstanding. Paramount holds a 100% working interest in the Grassy Mountain Gold Project in Oregon and a 100% interest in the Sleeper Gold Project in Nevada. Paramount's strategy is to create value through exploring and developing its mineral properties and to maximize value for shareholders by selling assets to established producers, or entering joint ventures with producers, or constructing and operating mines for its own account. For more information, visit the company website at

Paratek Pharmaceuticals (PRTK)

Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company focused on development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, if approved, will be the first in a new class of tetracyclines with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA for target indications. For more information, visit the company website at

PDL BioPharma (PDLI)

PDL BioPharma (NASDAQ: PDLI) PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In late 2012, PDL began providing alternative sources of capital through royalty monetization and debt facilities and in 2016, began making equity investments in commercial stage companies, the first being Noden Pharma DAC. PDL has committed over $1.4 billion and funded approximately $1.1 billion in these investments to date. For more information, visit the company website at

Pershing Gold (PGLC)

Pershing Gold (NASDAQ: PGLC) is an emerging gold producer whose primary asset is the Relief Canyon Mine in Pershing County, Nevada. Relief Canyon includes three historic open-pit mines and a state-of-the-art, fully permitted and constructed heap-leach processing facility. Pershing Gold's landholdings cover approximately 25,000 acres that include the Relief Canyon Mine asset and lands surrounding the mine in all directions. This land package provides Pershing Gold with the opportunity to expand the Relief Canyon Mine deposit and to explore and make new discoveries on nearby lands. For more information, visit the company website at

Pfenex (PFNX)

Pfenex (NYSE: PFNX) is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value, difficult to manufacture proteins. The company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo for treatment of osteoporosis, and PF582, a biosimilar candidate to Lucentis, for potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, therapeutic equivalents to reference listed drug products, and next generation biologics. For more information, visit the company website at

PhaseRx (PZRX)

PhaseRx (NASDAQ: PZRX) is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. For more information, visit the company website at

Pieris Pharmaceuticals (PIRS)

Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. The company's pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. For more information, visit the company website at

Plug Power (PLUG)

Plug Power (NASDAQ: PLUG) has taken hydrogen and fuel cell technology from concept to commercialization. Plug Power has revolutionized the material handling industry with its full-service GenKey solution, which is designed to increase productivity, lower operating costs and reduce carbon footprints in a reliable, cost-effective way. The company's GenKey solution couples together all the necessary elements to power, fuel and serve a customer. With proven hydrogen and fuel cell products, Plug Power replaces lead acid batteries to power electric industrial vehicles, such as the lift trucks customers use in their distribution centers. For more information, visit the company website at

Pluristem Therapeutics (PSTI)

Pluristem Therapeutics (NASDAQ: PSTI) develops placenta-based cell therapy products. The company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells and is entering late-stage trials in several indications. The cell products release a range of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration. For more information, visit the company website at

Pointer Telocation (PNTR)

Pointer Telocation (NASDAQ: PNTR) is focused on the Mobile Resource Management (MRM) market and a pioneer in the Connected Car segment. Pointer has developed a full suite of tools, technology and services to respond to the market's needs. Future vehicles will be networked with the outside world, optimizing the in-car experience. Pointer's cloud-based software-as-a-service (SAAS) platform extracts and captures an organization's critical mobility data points – from office, drivers, routes, points-of-interest, logistic-network, vehicles, trailers, containers and cargo. The SAAS platform analyzes the raw data converting it into valuable information for Pointer's customers. For more information, visit the company website at

Presbia (LENS)

Presbia (NASDAQ: LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014. For more information, visit the company website at

Pressure BioSciences (PBIO)

Pressure BioSciences (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. There are over 100 publications citing the advantages of the PCT platform over competitive methods. For more information, visit the company website at

Pretivm (PVG)

Pretivm (NYSE: PVG) is focused on creating value through gold by ramping up production of the 100%-owned underground Brucejack gold mine. Commercial production was announced July 2017. Located 65 kilometers north of the town of Stewart in northern British Columbia. A feasibility study completed in 2014 and updated in December 2016 has outlined Proven and Probable mineral reserves in Brucejack's Valley of the Kings comprising 8.1 million ounces of gold (15.6 million tonnes grading 16.1 grams per tonne gold). Pretivm is advancing Brucejack to production as a 2,700 tonnes per day underground mine. For more information, visit the company website at

ProLung (LUNG)

ProLung (NASDAQ: LUNG) is the leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer. The company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung's predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the U.S. For more information, visit the company website at

Protalix BioTherapeutics (PLX)

Protalix BioTherapeutics (NYSE: PLX) is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix's expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa. Protalix has a substantial development pipeline. For more information, visit the company website at

pSivida (PSDV)

pSivida (NASDAQ: PSDV) is a leader in the development of sustained release drug for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the US and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert micro-insert for posterior segment uveitis is being independently developed. For more information, visit the company website at

Pulmatrix (PULM)

Pulmatrix (NASDAQ: PULM) is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The company's product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, a proprietary inhaled itraconazole formulation that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. For more information, visit the company website at

RedHill Biopharma (RDHL)

RedHill Biopharma (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill promotes two gastrointestinal products in the U.S. - Donnatal®, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, and EnteraGam®, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools, and has a U.S. commercialization agreement with ParaPRO for Esomeprazole Strontium Delayed-Release Capsules 49.3 mg. For more information, visit the company website at

RegeneRx Biopharmaceuticals (RGRX)

RegeneRx Biopharmaceuticals (OTC: RGRX) is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia and has patents and patent applications covering its products in many countries throughout the world. For more information, visit the company website at

Resonant (RESN)

Resonant (NASDAQ: RESN) is creating innovative software, intellectual property and a services platform that has the ability to increase designer efficiency, reduce the time to market and lower unit costs in the designs of filters for radio frequency (RF) front-ends for the mobile device industry. The RF front-end is the circuitry in a mobile device responsible for analog signal processing and is located between the device's antenna and its digital baseband. The RF front-end industry is undergoing dramatic increases in growth and complexity. For more information, visit the company website at

RespireRx Pharmaceuticals (RSPI)

RespireRx Pharmaceuticals (OTC: RSPI) is a leader in the development of medicines for neurologically controlled respiratory disorders, with a focus on sleep apneas and drug-induced respiratory depression. The company owns patents and patent applications, and holds exclusive licenses, for certain families of chemical compounds that claim the chemical structures and their use in the treatment of these and other disorders. For more information, visit the company website at

Revolution Lighting Technologies (RVLT)

Revolution Lighting Technologies (NASDAQ: RVLT) is a leader in the design, manufacture, marketing, and sale of LED lighting solutions focusing on the industrial, commercial and government markets in the United States, Canada, and internationally. Through advanced LED technologies, Revolution Lighting has created an innovative lighting company that offers a comprehensive advanced product platform of high-quality interior and exterior LED lamps and fixtures, including signage and control systems. For more information, visit the company website at

ReWalk Robotics (RWLK)

ReWalk Robotics (NASDAQ: RWLK) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The company mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information, visit the company website at

Rexahn Pharmaceuticals (RNN)

Rexahn Pharmaceuticals (NYSE: RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The company's mission is to improve the lives of cancer patients by developing next generation cancer therapies designed to maximize efficacy while minimizing toxicity and side effects associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. The company has a broad oncology pipeline that includes three anti-cancer compounds currently in clinical development. For more information, visit the company website at

Ritter Pharmaceuticals (RTTR)

Ritter Pharmaceuticals (NASDAQ: RTTR) develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. For more information, visit the company website at

Sandstorm Gold (SAND)

Sandstorm Gold (NYSE: SAND) is a gold royalty company. Sandstorm provides upfront financing to gold mining companies that are looking for capital and in return, receives the right to a percentage of the gold produced from a mine, for the life of the mine. Sandstorm has acquired a portfolio of 160 streams and royalties and plans to grow and diversify its low cost production profile by making acquisitions. For more information, visit the company website at

Savara (SVRA)

Savara (NASDAQ: SVRA) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises Molgradex, a phase 3 stage inhaled granulocyte-macrophage colony-stimulating factor for pulmonary arterial proteinosis, AeroVanc, an inhaled vancomycin for MRSA infection in Cystic Fibrosis in preparation for phase 3, and Aironite, an inhaled sodium nitrite in phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions. For more information, visit the company website at


SCYNEXIS (NASDAQ: SCYX) is a biotechnology company committed to impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit the company website at

SeaSpine (SPNE)

SeaSpine (NASDAQ: SPNE) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal instrumentation solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine currently markets its products in the United States and in over 30 countries worldwide. For more information, visit the company website at

Second Sight (EYES)

Second Sight (NASDAQ: EYES) develops, manufactures and markets innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and manufactures the Argus® II Retinal Prosthesis System. Second Sight is currently conducting a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis that is intended to restore some vision to individuals who are blind due to many causes other than preventable or treatable conditions. For more information, visit the company website at

Sensus Healthcare (SRTS)

Sensus Healthcare (NASDAQ: SRTS) is a medical device company that is committed to providing non-invasive and cost-effective treatment options for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit the company website at

Sierra Metals (SMTS)

Sierra Metals (NYSE: SMTS) is a polymetallic mining company with production from its Yauricocha mine in Peru, the Bolivar mine in Chihuahua, Mexico and the Cusihuiriachic property in Chihuahua, Mexico. Sierra is focused on increasing production volume and growing mineral resources. Sierra has recently had several new discoveries and still has additional brownfield exploration opportunities at all three mines in Peru and Mexico. Sierra has large land packages at all three mines with several prospective regional targets providing longer term exploration upside and mineral resource growth potential. For more information, visit the company website at

Smith Micro (SMSI)

Smith Micro (NASDAQ: SMSI) develops software to simplify and enhance the mobile experience, providing solutions to some of the leading wireless service providers, device manufacturers, and enterprise businesses around the world. From optimizing wireless networks to uncovering customer experience insights, and from streamlining Wi-Fi access to ensuring family safety, Smith Micro provides solutions to enrich today's connected lifestyles. The company portfolio includes a wide range of products for creating, sharing and monetizing rich content, such as visual messaging, video streaming, and 2D/3D graphics applications. For more information, visit the company website at

Soligenix (SNGX)

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's BioTherapeutics business segment is developing a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, a first-in-class innate defense regulator technology for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation including pediatric Crohn's disease and acute radiation enteritis. For more information, visit the company website at

Solitario Zinc (XPL)

Solitario Zinc (NYSE: XPL) is an emerging zinc exploration and development company. Besides Solitario's joint venture with Milpo on its high-grade Florida Canyon zinc project in Peru, Solitario also holds a 50% joint venture interest (Teck Resources Ltd. holds the other 50% interest) in the high-grade, open pitable Lik zinc deposit in Alaska, and a 7.6% equity interest in Vendetta Mining. Solitario's Management and Directors hold approximately 9.2% of the company's 58.45 million shares outstanding. Solitario's cash balance and marketable securities stand at approximately US$15 million. For more information, visit the company website at

Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals (NASDAQ: SNOA) is a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin conditions. Sonoma believes its products, which are sold throughout the United States and internationally, have improved patient outcomes for more than 5 million patients globally by treating and reducing certain topical skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain and harmful inflammatory responses. For more information, visit the company website at

Sophiris Bio (SPHS)

Sophiris Bio (NASDAQ: SPHS) is a late-stage, clinical biopharmaceutical company developing topsalysin for the treatment of patients with urological diseases. Topsalysin is in Phase 2 clinical development for the focal treatment of localized prostate cancer as well as Phase 3 clinical development for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). More than 400 patients have received topsalysin, which continues to appear to be safe and well tolerated. For more information, visit the company website at

Spectrum Pharmaceuticals (SPPI)

Spectrum Pharmaceuticals (NASDAQ: SPPI) is a biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage phase 2 and Phase 3 studies. For more information, visit the company website at


SRAX (NASDAQ: SRAX) is an advertising technology company providing the tools to automate digital marketers and content owners' campaigns across digital channels. SRAX's tools amplify performance and maximize profits for brands in the healthcare, CPG, automotive, wellness and lifestyle verticals through an omnichannel approach that integrates all aspects of the marketing experience into one platform. The company's machine-learning technology identifies brands' core consumers and their characteristics discovering new and measurable opportunities to target, reach and monetize audiences driving online and offline sales lift. For more information, visit the company website at

SteadyMed (STDY)

SteadyMed (NASDAQ: STDY) is a specialty pharmaceutical company focused on development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's pre-filled, sterile, single use, disposable, PatchPump® infusion system, with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has an exclusive license and supply agreement with Cardiome Pharma for the commercialization of Trevyent in Europe, Canada and the Middle East. For more information, visit the company website at

Stemline Therapeutics (STML)

Stemline Therapeutics (NASDAQ: STML) is a clinical stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a cell surface receptor overexpressed on BPDCN and a variety of other hematologic cancers. SL-401 was granted Breakthrough Therapy Designation (BTD) for the treatment of patients with BPDCN. A pivotal phase 2 trial with SL-401 in BPDCN has completed enrollment in Stages 1, 2 and 3 of the trial; to ensure ongoing patient access to SL-401, an additional cohort, Stage 4, is enrolling. For more information, visit the company website at

STRATA Skin Sciences (SSKN)

STRATA Skin Sciences (NASDAQ: SSKN) is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; the STRATAPEN™ MicroSystem, marketed specifically for the intended use of micropigmentation; and Nordlys, a multi-technology aesthetic laser device. For more information, visit the company website at

Strongbridge Biopharma (SBBP)

Strongbridge Biopharma (NASDAQ: SBBP) is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the company has a clinical-stage pipeline of therapies for rare endocrine diseases. For more information, visit the company website at

Summit Therapeutics (SMMT)

Summit Therapeutics (NASDAQ: SMMT) is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. For more information, visit the company website at

Superconductor Technologies (SCON)

Superconductor Technologies (NASDAQ: SCON) is a global leader in superconducting innovation. Its Conductus® superconducting wire platform offers high performance, cost-effective and scalable superconducting wire. With 100 times the current carrying capacity of conventional copper and aluminum, superconducting wire offers zero resistance with extreme high current density. This provides a significant benefit for electric power transmission and enables much smaller or more powerful magnets for motors, generators, energy storage and medical equipment. The company has more than 100 patents as well as proprietary trade secrets and manufacturing expertise. For more information, visit the company website at

Synergy Pharmaceuticals (SGYP)

Synergy Pharmaceuticals (NASDAQ: SGYP) is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. The company has pioneered discovery, research and development efforts on analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy's proprietary GI platform includes one commercial product TRULANCE and a second lead product candidate, dolcanatide. For more information, visit the company website at

Synthetic Biologics (SYN)

Synthetic Biologics (NYSE: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore patient health. The company's lead candidates poised for phase 3 development are: (1) SYN-004 - designed to protect the gut microbiome from the effects of certain commonly used intravenous antibiotics for the prevention of C. difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance; and (2) SYN-010 - intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. For more information, visit the company website at

TearLab (TEAR)

TearLab (NASDAQ: TEAR) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. To date, TearLab has placed over 5,000 devices worldwide and had more than 8 million tests performed on the TearLab Osmolarity System globally since the commercial launch in 2012. For more information, visit the company website at

Tecogen (TGEN)

Tecogen (NASDAQ: TGEN) designs, manufactures, sells, installs and maintains high efficiency, ultra-clean, cogeneration products including natural gas engine-driven combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer's carbon footprint. Tecogen has shipped more than 2,500 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, visit the company website at

Tetraphase Pharmaceuticals (TTPH)

Tetraphase Pharmaceuticals (NASDAQ: TTPH) is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in Phase 1 clinical trials. For more information, visit the company website at

Tonix Pharmaceuticals (TNXP)

Tonix Pharmaceuticals (NASDAQ: TNXP) is developing innovative pharmaceutical and biological products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine. For more information, visit the company website at

Trevena (TRVN)

Trevena (NASDAQ: TRVN) is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has discovered four novel and differentiated drug candidates, including OLINVO. Trevena also has discovered TRV250, in early clinical development for the treatment of migraine, and TRV734 for pain. The company maintains an early stage portfolio of drug discovery programs. For more information, visit the company website at

Trovagene (TROV)

Trovagene (NASDAQ: TROV) is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. For more information, visit the company website at

Tyme Technologies (TYME)

Tyme Technologies (NASDAQ: TYME) is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. For more information, visit the company website at

U.S. Gold (USAU)

U.S. Gold (NASDAQ: USAU) is a U.S.-focused gold exploration and development company. U.S. Gold Corp. has a portfolio of development and exploration properties. Copper King is located in South East Wyoming and has an historical Preliminary Economic Assessment (PEA) done by Mine Development Associates in 2012 for Strathmore Minerals Corporation. Keystone and Gold Bar North are exploration properties located on the Cortez trend in Nevada, identified and consolidated by Dave Mathewson, V.P. Head of Exploration. For more information, visit the company website at

UQM Technologies (UQM)

UQM Technologies (NYSE: UQM) is a developer and manufacturer of power-dense, high-efficiency electric motors, generators, power electronic controllers and fuel cell compressors for the commercial truck, bus, automotive, marine, and industrial markets. A major emphasis for UQM is developing propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles. UQM is TS 16949 and ISO 14001 certified and located in Longmont, Colorado. For more information, visit the company website at

Ur-Energy (URG)

Ur-Energy (NYSE MKT: URG) is engaged in uranium mining, recovery and processing activities, including the acquisition, exploration, development and operation of uranium mineral properties in the United States. The company has produced, packaged and shipped more than 2 million pounds from Lost Creek since the commencement of operations. Applications are under review by various agencies to incorporate its LC East project area into the Lost Creek permits, and it has begun to submit applications for permits and licenses to construct and operate at the Shirley Basin Project. For more information, visit the company website at

Uranium Energy (UEC)

Uranium Energy (NYSE: UEC) is a uranium mining and exploration company. The company's fully-licensed Hobson Processing Facility is central to all of its projects in South Texas, including the Palangana ISR mine, the permitted Goliad ISR project and the development-stage Burke Hollow ISR project. In Wyoming, UEC controls the permitted Reno Creek ISR project. Additionally, the company controls a pipeline of advanced-stage projects in Arizona, Colorado, New Mexico, and Paraguay. For more information, visit the company website at

Urogen Pharma (URGN)

Urogen Pharma (NASDAQ: URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in urology. The company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer. For more information, visit the company website at

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (NASDAQ: VNDA) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more information, visit the company website at

Vascular Biogenics (VBLT)

Vascular Biogenics (NASDAQ: VBLT) operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate is a targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months and has been observed to be well-tolerated in >200 cancer patients with observed efficacy signals in an "all comers" phase 1 trial as well as in three tumor-specific Phase 2 studies. For more information, visit the company website at

VBI Vaccines (VBIV)

VBI Vaccines (NASDAQ: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI's first marketed product is Sci-B-Vac™, a hepatitis B vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI's eVLP Platform technology allows for the development of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines. For more information, visit the company website at

Veru Healthcare (VERU)

Veru Healthcare (NASDAQ: VERU) (formerly, NASDAQ: FHCO) is a biopharmaceutical company focused on urology and oncology. Veru utilizes FDA's 505(b)(2) regulatory approval pathway, which allows for potentially expedited regulatory approval based on a previously established safety and efficacy profile, to develop and commercialize drug candidates. Veru also develops products under the traditional new drug application pathway. The company is currently developing drug product candidates for benign prostatic hyperplasia, hot flashes associated with prostate cancer hormone treatment, male infertility and novel oral chemotherapy for a variety of malignancies, including metastatic prostate, breast and ovarian cancers. For more information, visit the company website at

Vical (VICL)

Vical (NASDAQ: VICL) develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. For more information, visit the company website at

Viking Therapeutics (VKTX)

Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. For more information, visit the company website at

Vista Gold (VGZ)

Vista Gold (NYSE: VGZ) is a well-funded gold project developer. The company's principal asset is its flagship Mt Todd gold project in Northern Territory, Australia. Mt Todd is one of the largest undeveloped gold projects in Australia. For more information, visit the company website at

Vitality Biopharma (VBIO)

Vitality Biopharma (OTCQB: VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. The company has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. For more information, visit the company website at

Viveve Medical (VIVE)

Viveve Medical (NASDAQ: VIVE) is a women's health and wellness company committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve System, that delivers the GENEVEVE treatment, incorporates clinically-proven, cryogen-cooled, monopolar radiofrequency (CMRF) to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session. The Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis. For more information, visit the company website at

VolitionRx (VNRX)

VolitionRx (NYSE: VNRX) is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. For more information, visit the company website at

vTv Therapeutics (VTVT)

vTv Therapeutics (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness. The company's lead drug candidates were discovered with its high-throughput drug discovery platform, TTP Translational Technology®, which translates the functional modulation of human proteins into safe and effective medicines. For more information, visit the company website at

Vuzix (VUZI)

Vuzix (NASDAQ: VUZI) is a supplier of Smart-Glasses, Augmented Reality (AR) and Virtual Reality (VR) technologies and products for the consumer and enterprise markets. The company's products include personal display and wearable computing devices that offer users a portable high quality viewing experience, provide solutions for mobility, wearable displays and virtual and augmented reality. Vuzix holds 51 patents and 39 additional patents pending and numerous IP licenses in the Video Eyewear field. The company has won multiple Consumer Electronics Show awards for innovation and several wireless technology innovation awards among others. For more information, visit the company website at

Western Copper and Gold (WRN)

Western Copper and Gold (NYSE: WRN) is developing the Casino project into Canada's Premier Copper-Gold Mine. The company holds significant gold, copper and molybdenum resources and reserves in its Casino Project located in the Yukon, Canada. Casino contains 8.9 million ounces of gold, 4.5 billion pounds of copper, 483 million pounds of molybdenum and 65 million ounces of silver in proven & probable reserves. For more information, visit the company website at


XOMA (NASDAQ: XOMA) has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the company's efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. For more information, visit the company website at

Yield10 Bioscience (YTEN)

Yield10 Bioscience (NASDAQ: YTEN) is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 leverages its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops. For more information, visit the company website at


ZIOPHARM Oncology (NASDAQ: ZIOP) is a biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. For more information, visit the company website at

Zynerba Pharmaceuticals (ZYNE)

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is dedicated to improving the lives of people with severe health conditions where there is a high unmet medical need by developing and commercializing pharmaceutically-produced transdermal cannabinoid medicines designed to meet the rigorous efficacy and safety standards established by global regulatory agencies. Through the discovery and development of these life-changing medicines, Zynerba seeks to improve the lives of patients battling severe, chronic health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. For more information, visit the company website at


Learn How to Become a Client-Partner

We have a full suite of powerful communications tools as well as an expansive network of more than 5,000 key distribution points. Interested in putting it all to work for you? Leveraging a professional team of journalists and writers, NNW can introduce you to a wide audience of investors, consumers, journalists and the general public.

If would like to work with us, visit our Become a Client-Partner page.


Contact us: 212.418.1217